NASDAQ:MYMD

MyMD Pharmaceuticals Competitors

$5.75
-0.09 (-1.54 %)
(As of 06/18/2021 07:34 PM ET)
Add
Compare
Today's Range
$5.61
$5.85
50-Day Range N/A
52-Week Range
$3.30
$13.94
Volume1.09 million shs
Average Volume452,399 shs
Market Capitalization$212.06 million
P/E RatioN/A
Dividend YieldN/A
Beta0.19

MyMD Pharmaceuticals (NASDAQ:MYMD) Vs. IDXX, NTLA, QDEL, NEOG, OCDX, and HSKA

Should you be buying MYMD stock or one of its competitors? Companies in the industry of "diagnostic substances" are considered alternatives and competitors to MyMD Pharmaceuticals, including IDEXX Laboratories (IDXX), Intellia Therapeutics (NTLA), Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), and Heska (HSKA).

MyMD Pharmaceuticals (NASDAQ:MYMD) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for MyMD Pharmaceuticals and IDEXX Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MyMD Pharmaceuticals0000N/A
IDEXX Laboratories00503.00

IDEXX Laboratories has a consensus price target of $474.60, suggesting a potential downside of 21.04%. Given IDEXX Laboratories' higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than MyMD Pharmaceuticals.

Profitability

This table compares MyMD Pharmaceuticals and IDEXX Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MyMD PharmaceuticalsN/A-38.60%-34.99%
IDEXX Laboratories23.59%131.51%31.25%

Valuation and Earnings

This table compares MyMD Pharmaceuticals and IDEXX Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A
IDEXX Laboratories$2.71 billion18.94$581.78 million$6.7189.58

IDEXX Laboratories has higher revenue and earnings than MyMD Pharmaceuticals.

Institutional and Insider Ownership

14.0% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of IDEXX Laboratories shares are held by institutional investors. 0.3% of MyMD Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

MyMD Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Summary

IDEXX Laboratories beats MyMD Pharmaceuticals on 10 of the 11 factors compared between the two stocks.

Intellia Therapeutics (NASDAQ:NTLA) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Intellia Therapeutics and MyMD Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellia Therapeutics-288.47%-33.89%-25.38%
MyMD PharmaceuticalsN/A-38.60%-34.99%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intellia Therapeutics and MyMD Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellia Therapeutics021202.86
MyMD Pharmaceuticals0000N/A

Intellia Therapeutics presently has a consensus target price of $79.00, suggesting a potential upside of 4.06%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than MyMD Pharmaceuticals.

Risk and Volatility

Intellia Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intellia Therapeutics and MyMD Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$57.99 million89.23$-134,230,000.00($2.40)-31.63
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A

MyMD Pharmaceuticals has lower revenue, but higher earnings than Intellia Therapeutics.

Institutional and Insider Ownership

94.3% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 14.0% of MyMD Pharmaceuticals shares are held by institutional investors. 5.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 0.3% of MyMD Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Intellia Therapeutics beats MyMD Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Quidel and MyMD Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
MyMD Pharmaceuticals0000N/A

Quidel presently has a consensus price target of $149.75, indicating a potential upside of 31.59%. Given Quidel's higher possible upside, equities analysts plainly believe Quidel is more favorable than MyMD Pharmaceuticals.

Valuation & Earnings

This table compares Quidel and MyMD Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$1.66 billion2.91$810.29 million$19.555.82
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A

Quidel has higher revenue and earnings than MyMD Pharmaceuticals.

Institutional & Insider Ownership

84.1% of Quidel shares are held by institutional investors. Comparatively, 14.0% of MyMD Pharmaceuticals shares are held by institutional investors. 2.7% of Quidel shares are held by company insiders. Comparatively, 0.3% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Quidel has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Profitability

This table compares Quidel and MyMD Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel50.91%92.33%63.88%
MyMD PharmaceuticalsN/A-38.60%-34.99%

Summary

Quidel beats MyMD Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

92.3% of Neogen shares are owned by institutional investors. Comparatively, 14.0% of MyMD Pharmaceuticals shares are owned by institutional investors. 0.9% of Neogen shares are owned by insiders. Comparatively, 0.3% of MyMD Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Neogen and MyMD Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.66%8.03%7.35%
MyMD PharmaceuticalsN/A-38.60%-34.99%

Earnings and Valuation

This table compares Neogen and MyMD Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million11.45$59.47 million$0.5679.88
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A

Neogen has higher revenue and earnings than MyMD Pharmaceuticals.

Risk and Volatility

Neogen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Neogen and MyMD Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
MyMD Pharmaceuticals0000N/A

Neogen presently has a consensus price target of $20.3750, indicating a potential downside of 54.45%. Given Neogen's higher probable upside, research analysts clearly believe Neogen is more favorable than MyMD Pharmaceuticals.

Summary

Neogen beats MyMD Pharmaceuticals on 10 of the 11 factors compared between the two stocks.

Ortho Clinical Diagnostics (NASDAQ:OCDX) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ortho Clinical Diagnostics and MyMD Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
MyMD Pharmaceuticals0000N/A

Ortho Clinical Diagnostics presently has a consensus price target of $24.5455, suggesting a potential upside of 14.54%. Given Ortho Clinical Diagnostics' higher probable upside, equities analysts clearly believe Ortho Clinical Diagnostics is more favorable than MyMD Pharmaceuticals.

Valuation and Earnings

This table compares Ortho Clinical Diagnostics and MyMD Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical Diagnostics$1.77 billion2.70$-211,900,000.00$0.2973.90
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A

MyMD Pharmaceuticals has lower revenue, but higher earnings than Ortho Clinical Diagnostics.

Profitability

This table compares Ortho Clinical Diagnostics and MyMD Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
MyMD PharmaceuticalsN/A-38.60%-34.99%

Insider & Institutional Ownership

14.0% of MyMD Pharmaceuticals shares are held by institutional investors. 0.3% of MyMD Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Ortho Clinical Diagnostics beats MyMD Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Heska (NASDAQ:HSKA) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Heska and MyMD Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heska$197.32 million12.20$-14,400,000.00($0.26)-887.92
MyMD Pharmaceuticals$1.58 million134.22$-17,580,000.00N/AN/A

Heska has higher revenue and earnings than MyMD Pharmaceuticals.

Profitability

This table compares Heska and MyMD Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heska-3.19%0.77%0.56%
MyMD PharmaceuticalsN/A-38.60%-34.99%

Analyst Ratings

This is a summary of current ratings for Heska and MyMD Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heska00403.00
MyMD Pharmaceuticals0000N/A

Heska presently has a consensus target price of $225.00, suggesting a potential downside of 2.54%. Given Heska's higher possible upside, equities research analysts plainly believe Heska is more favorable than MyMD Pharmaceuticals.

Risk & Volatility

Heska has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

Institutional and Insider Ownership

94.9% of Heska shares are owned by institutional investors. Comparatively, 14.0% of MyMD Pharmaceuticals shares are owned by institutional investors. 8.6% of Heska shares are owned by company insiders. Comparatively, 0.3% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Heska beats MyMD Pharmaceuticals on 9 of the 11 factors compared between the two stocks.


MyMD Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$601.05-0.5%$51.26 billion$2.71 billion77.36Increase in Short Interest
Intellia Therapeutics logo
NTLA
Intellia Therapeutics
1.2$75.92-0.8%$5.17 billion$57.99 million-30.86Insider Selling
Quidel logo
QDEL
Quidel
2.0$113.80-0.9%$4.84 billion$1.66 billion5.23Analyst Report
Neogen logo
NEOG
Neogen
1.4$44.73-2.9%$4.79 billion$418.17 million77.12Gap Up
Ortho Clinical Diagnostics logo
OCDX
Ortho Clinical Diagnostics
1.8$21.43-3.2%$4.77 billion$1.77 billion73.90News Coverage
Gap Up
Heska logo
HSKA
Heska
1.5$230.86-0.5%$2.41 billion$197.32 million-271.60
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.61-7.2%$2.20 billion$638.60 million-13.96Analyst Report
Gap Up
Lantheus logo
LNTH
Lantheus
1.5$24.62-0.8%$1.66 billion$339.41 million-136.77
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.7$27.78-0.8%$1.10 billion$7.42 million-15.18High Trading Volume
News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$20.39-2.9%$883.50 million$253.67 million10.20
Aspira Women's Health logo
AWH
Aspira Women's Health
1.3$5.64-4.6%$631.38 million$4.65 million-7.94Gap Up
Quotient logo
QTNT
Quotient
1.6$4.35-0.0%$441.64 million$43.38 million-3.69High Trading Volume
Lucira Health logo
LHDX
Lucira Health
1.2$4.85-0.8%$187.08 million$270,000.00-0.31Analyst Upgrade
Nymox Pharmaceutical logo
NYMX
Nymox Pharmaceutical
0.8$1.46-6.2%$120.28 millionN/A-9.13Gap Up
ICCC
ImmuCell
1.3$9.72-3.3%$75.19 million$15.34 million-54.00Increase in Short Interest
Gap Up
Trinity Biotech logo
TRIB
Trinity Biotech
0.6$2.99-3.7%$62.50 million$101.98 million24.92Increase in Short Interest
News Coverage
Gap Up
ABIO
ARCA biopharma
0.9$3.61-1.4%$52.02 millionN/A-1.81Decrease in Short Interest
News Coverage
Biomerica logo
BMRA
Biomerica
1.6$3.97-2.5%$48.84 million$6.69 million-8.63Decrease in Short Interest
Gap Down
Achieve Life Sciences logo
ACHV
Achieve Life Sciences
1.8$7.72-7.1%$47.59 millionN/A-1.48Decrease in Short Interest
Gap Up
This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.